#BNT162b2 AND #COVAXIN Vaccines: Live viral #challenge models

1

https://health.economictimes.indiatimes.com/news/pharma/animal-study-proved-covid-vaccines-efficacy-bharat-biotech/78077080

“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral #challenge model,” tweeted the #Hyderabad based firm.

More info
https://www.precisionvaccinations.com/vaccines/covaxin-sars-cov-2-vaccine

[IDK much about #COVAXIN]

2

https://www.fiercebiotech.com/research/pfizer-biontech-report-strong-immune-response-animals-to-covid-19-mrna-vaccine-candidate

Now the companies are reporting that the most advanced candidate, #BNT162b2, performed well in trials in which mice and macaques were infected with the coronavirus after inoculation.

Pfizer and BioNTech reported that after one shot and a booster shot, the macaques that had been #challenged with the COVID-19 virus had no viral RNA in their lower respiratory tracts, as compared to non-immunized animals, most of which did show evidence of the viral RNA.

[#BNT162b2 is an mRNA vaccine candidate, so there are #PEG concerns]

#SARSCoV2 #COVAXIN

vaccine #challenge plasma macaque animal study covid “sars-cov-2” booster viral model immune

[It would appear vaccinated animals are being challenged with live (wild) virus with both of these vaccines. There will be others as well, like the one being developed at Baylor by Hotez and associates.]